Sakar Healthcare Q2FY27 Results: Net Profit Rises 149% to Rs 11.30 Crore, Revenue Jumps 51.9%

Ahmedabad-based Sakar Healthcare Ltd (NSE: SAKAR) announced its unaudited financial results for the quarter and half year ended September 30, 2026, reporting strong growth in revenue, profitability and operational performance. The pharmaceutical manufacturer, which operates a research-driven, API-integrated, EU-GMP-approved oncology oral and injectable manufacturing facility, attributed its performance to new oncology approvals, strong demand across geographies, an improved oncology product mix, operating leverage and disciplined cost management.

For Q2FY27, Sakar Healthcare's net profit increased 149 per cent year-on-year to Rs 11.30 crore, compared with Rs 4.54 crore in Q2FY26. The profit after Tax (PAT) margin improved to 13 per cent from 8 per cent in the corresponding quarter last year. EBITDA rose 114 per cent year-on-year to Rs 24.34 crore from Rs 11.35 crore, while the EBITDA margin increased to 28 per cent from 20 per cent. Revenue from operations grew 51.9 per cent to Rs 87.41 crore in Q2FY27, compared with Rs 57.56 crore in Q2FY26.

For the first half of FY27, the company reported net profit of Rs 21.59 crore, an increase of 134 per cent from Rs 9.21 crore in H1FY26. The PAT margin improved to 13 per cent from 8 per cent. EBITDA increased 90 per cent year-on-year to Rs 45.59 crore from Rs 24.06 crore, while the EBITDA margin rose to 28 per cent from 22 per cent. Revenue from operations grew 45.4 per cent to Rs 160.39 crore, compared with Rs 110.29 crore in the corresponding period of the previous financial year.

Commenting on the results, Sanjay Shah, Managing Director of Sakar Healthcare, said Q2FY27 marked meaningful progress for the company's oncology business, supported by developments in regulatory approvals, technology transfers and global market access. These milestones have strengthened its international presence, deepened relationships with global partners and established a foundation for future growth.

Shah highlighted the commencement of commercial supplies from the company's EU-GMP-approved, API-integrated oncology facility as an important milestone. Supported by in-house API capabilities and ongoing technology transfers, the company is strengthening its integrated manufacturing platform, improving supply-chain control and expanding its ability to serve regulated markets. Looking ahead, Sakar Healthcare remains optimistic about opportunities arising from its expanding oncology portfolio, growing pipeline and international partnerships. The company expects these developments to support export growth, improved capacity utilisation and operating efficiencies, contributing to sustainable long-term growth.

During Q2FY27 and H1FY27, Sakar Healthcare executed approximately 70 oncology product contracts, with 45 additional commercial discussions underway. The company shared 350 dossiers globally, of which 191 have been submitted and 22 have received marketing authorisations (MAs). It also received 14 new oncology approvals across the European Union (EU), the U.K. and Canada, including six licensed-out marketing authorisations comprising four in the EU, one in the U.K. and one in Canada.

The company completed 36 EU marketing authorisation filings, including 16 owned filings. It also submitted 33 site variations covering 18 cytotoxic molecules across the EU and the U.K., of which 11 have been approved in stringent markets. In addition, 33 oncology product technology transfer projects are currently underway.

On the API front, Sakar Healthcare developed 21 APIs in-house, including 16 APIs with Written Confirmation. Eight products have been commercialised, while two of the company's seven Certificate of Suitability (CEP) applications have been approved and five remain under process. Commercial supplies to domestic and international markets have also commenced from its API-integrated, EU-GMP-approved oncology finished-dosage-form (FDF) facility.

Further regulatory developments included six additional product site variations for Accord cleared by the European Medicines Agency (EMA), taking the total to eight out of 11 molecules. The company's partners in the U.K. and Germany also received three product approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and EMA, comprising two approvals in the U.K. and one in Germany.

Sakar Healthcare has also expanded its oncology coverage across multiple cancer indications, including breast, lung, prostate, stomach, head and neck, colorectal, ovarian, liver, kidney and thyroid cancers, as well as blood, bone marrow and lymph-related cancers.

Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Ltd is a publicly listed pharmaceutical manufacturer and exporter specialising in oncology, antibiotics and general formulations. The company operates EU-GMP- and WHO-GMP-certified manufacturing facilities equipped to produce oral solids, injectables, oral liquids and high-potency oncology products.

Its oncology division at Bavla is a research-driven, API-integrated facility focused on developing and commercialising complex cytotoxic formulations and APIs. With a presence in more than 60 countries, Sakar Healthcare works with multinational pharmaceutical companies through contract development and manufacturing organisation (CDMO), contract research and manufacturing services (CRAMS) and technology transfer collaborations. The company continues to expand its presence in regulated markets through research and development capabilities, regulatory expertise and sustainable manufacturing practices based on green chemistry principles.

Disclaimer: The article is for informational purposes only and not investment advice.